The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review

References

• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113. doi:10.1016/j.jaad.2018.11.058
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562. doi:10.1038/jid.2011.365
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–1039. doi:10.1001/archdermatol.2011.119
   PubMedGoogle Scholar
• Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. doi:10.3390/ijms20184347
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet Lond Engl. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375(4):345–356. doi:10.1056/NEJMoa1512711
   PubMed Web of Science ®Google Scholar
• Nakamura M, Lee K, Jeon C, et al. Guselkumab for the Treatment of Psoriasis: a Review of Phase III Trials. Dermatol Ther. 2017;7(3):281–292. doi:10.1007/s13555-017-0187-0
   PubMed Web of Science ®Google Scholar
• Enos CW, O’Connell KA, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States. JID Innov Skin Sci Mol Popul Health. 2021;1(2):100025. doi:10.1016/j.xjidi.2021.100025
   PubMedGoogle Scholar
• Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: what Does the Evidence Say? Am J Clin Dermatol. 2018;19(1):1–13. doi:10.1007/s40257-017-0328-3
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. doi:10.1016/j.jaad.2018.06.056
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Kurnool S, Nguyen NH, Proudfoot J, et al. High Body Mass Index is Associated with Increased Risk of Treatment Failure and Surgery in Biologic-treated Patients with Ulcerative Colitis. Aliment Pharmacol Ther. 2018;47(11):1472–1479. doi:10.1111/apt.14665
   PubMed Web of Science ®Google Scholar
• Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173–183. doi:10.1016/j.jbspin.2018.03.007
   PubMed Web of Science ®Google Scholar
• Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–446. doi:10.1016/j.jaad.2007.11.011
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol JEADV. 2011;25(9):1007–1011. doi:10.1111/j.1468-3083.2011.04065.x
   PubMed Web of Science ®Google Scholar
• Prussick R, Unnebrink K, Valdecantos WC. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis. J Drugs Dermatol JDD. 2015;14(8):864–868.
   PubMed Web of Science ®Google Scholar
• Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol. 2020;182(4):880–888. doi:10.1111/bjd.18327
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571–579. doi:10.1016/j.jaad.2009.11.012
   PubMed Web of Science ®Google Scholar
• Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol JEADV. 2022;36(10):1774–1783. doi:10.1111/jdv.18167
   PubMed Web of Science ®Google Scholar
• Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018;20:171. doi:10.1186/s13075-018-1669-x
   PubMed Web of Science ®Google Scholar
• Lin C, Ji H, Cai X, Yang W, Lv F, Ji L. The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: a systematic review and meta-analysis. Pharmacol Res. 2020;161:105216. doi:10.1016/j.phrs.2020.105216
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716. doi:10.1046/j.1445-2197.2003.02748.x
   PubMed Web of Science ®Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. J Dermatol Treat. 2022;33(7):2975–2982. doi:10.1080/09546634.2022.2089329
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Zangrilli A, Bavetta M, Bianchi L, Chimenti S, Saraceno R. Real-life 9-year experience with Adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol JEADV. 2017;31(2):304–311. doi:10.1111/jdv.13771
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: real-Life Multicenter Experience from the Czech Republic. Dermatol Ther. 2021;11(4):1345–1355. doi:10.1007/s13555-021-00556-2
   PubMed Web of Science ®Google Scholar
• Demirel N, Koç S, Erbağcı E, Hapa FA. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting. J Cosmet Dermatol. 2022;21(11):6215–6224. doi:10.1111/jocd.15217
   PubMed Web of Science ®Google Scholar
• Karpinska-Mirecka A, Bartosinska J, Krasowska D. The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment. Int J Environ Res Public Health. 2021;18(24). doi:10.3390/ijerph182413167
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Gargiulo L, et al. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatol Treat. 2019;30(5):424–429. doi:10.1080/09546634.2018.1528000
   PubMed Web of Science ®Google Scholar
• Petridis A, Panagakis P, Moustou E, et al. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece. J Eur Acad Dermatol Venereol JEADV. 2018;32(5):768–775. doi:10.1111/jdv.14802
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: a Real-World Study. Clin Drug Investig. 2021;41(10):917–925. doi:10.1007/s40261-021-01080-z
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther. 2010;23 Suppl 1:S14-19. doi:10.1111/j.1529-8019.2009.01281.x
   Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol JEADV. 2020;34(6):1240–1247. doi:10.1111/jdv.16202
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: a 52-Week Retrospective Study. Dermatol Ther. 2022;12(10):2309–2324. doi:10.1007/s13555-022-00795-x
   PubMed Web of Science ®Google Scholar
• Giunta A, Babino G, Ruzzetti M, Manetta S, Chimenti S, Esposito M. Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: a retrospective study. J Int Med Res. 2016;44(1 suppl):72–75. doi:10.1177/0300060515593254
   PubMedGoogle Scholar
• Hung Y, Lin Y, Chiu H, Huang Y. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv CHRONIC Dis. 2021;12. doi:10.1177/20406223211046685
   Web of Science ®Google Scholar
• Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol. 2014;41(8):690–696. doi:10.1111/1346-8138.12538
   PubMed Web of Science ®Google Scholar
• Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6). doi:10.1111/dth.15489
   Web of Science ®Google Scholar
• Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatol Treat. 2020;31(8):769–775. doi:10.1080/09546634.2019.1626973
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(7):1196–1207. doi:10.1111/jdv.14252
   PubMed Web of Science ®Google Scholar
• Egeberg A, Merola JF, Schäkel K, et al. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Front Med. 2022;9:1092688. doi:10.3389/fmed.2022.1092688
   Web of Science ®Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76. doi:10.1016/j.jaad.2021.06.883
   PubMed Web of Science ®Google Scholar
• Baloghova J, Feketeova E, Kolarcik P. Homocysteine Is a Marker of Increased Cardio-Cerebrovascular Disease Risk in Psoriatic Patients, but It Does Not Reflect the Effect of Biological Therapy in the Longitudinal Observation. Int J Clin Pract. 2022;2022:3820094. doi:10.1155/2022/3820094
   PubMed Web of Science ®Google Scholar